SUBSCRIBE
SUBSCRIBE
News   FDA

Australian Agency Approves Sandoz Recombinant DNA Human Growth Hormone Omnitrope

October 19, 2005 | 
1 min read
Sandoz has received approval from the Australian Therapeutic Goods Administration (TGA) to market the recombinant DNA human growth hormone Omnitrope. The TGA has recognized the safety and efficacy of Omnitrope by approving the product.
FDA Approvals
MORE ON THIS TOPIC
Finding Talented People. Big Hands with Magnifying Glass Recruiting People. vector
FDA
Prasad Under Probe for Promoting Workplace Toxicity, Staffers Say
February 27, 2026
 · 
2 min read
 · 
Tristan Manalac
Digital compass. Business strategic explorer, Vision crisis, Mission path, Agency creative, Digital strategy, Market decision, Achievement strategy, Financial stock, Company vision concepts
Policy
FDA Policy Tracker 2026: One-Trial Drug Applications, Guidelines for Personalized Therapies
February 27, 2026
 · 
7 min read
 · 
Heather McKenzie
FDA commissioner Marty Makary speaking on a Youtube video, wearing a dark suit and a blue tie
Regulatory
Makary Defends FDA’s Decision-Making Amid Contentious Rare Disease Rejections
February 27, 2026
 · 
2 min read
 · 
Tristan Manalac
Insights
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
February 26, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker